Related Experiment Video
Updated: Feb 17, 2026

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
Published on: June 9, 2017
ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After
Ödül Karayazi Atici1,2, Anna Urbanska1,2, Sesha Gopal Gopinathan1,2
1Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
Abstract:
Prolactin (PRL) acts as a survival factor for breast cancer cells, but the PRL signaling pathway and the mechanism are unknown. Previously, we identified the master chaperone, heat shock protein 90 (HSP90) α, as a prolactin-Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5) target gene involved in survival, and here we investigated the role of HSP90 in the mechanism of PRL-induced viability in response to DNA damage. The ataxia-telangiectasia mutated kinase (ATM) protein plays a critical role in the cellular response to double-strand DNA damage. We observed that PRL increased viability of breast cancer cells treated with doxorubicin or etoposide. The increase in cellular resistance is specific to the PRL receptor, because the PRL receptor antagonist, Δ1-9-G129R-hPRL, prevented the increase in viability. Two different HSP90 inhibitors, 17-allylamino-17-demethoxygeldanamycin and BIIB021, reduced the PRL-mediated increase in cell viability of doxorubicin-treated cells and led to a decrease in JAK2, ATM, and phosphorylated ATM protein levels. Inhibitors of JAK2 (G6) and ATM (KU55933) abolished the PRL-mediated increase in cell viability of DNA-damaged cells, supporting the involvement of each, as well as the crosstalk of ATM with the PRL pathway in the context of DNA damage. Drug synergism was detected between the ATM inhibitor (KU55933) and doxorubicin and between the HSP90 inhibitor (BIIB021) and doxorubicin. Short interfering RNA directed against ATM prevented the PRL-mediated increase in cell survival in two-dimensional cell culture, three-dimensional collagen gel cultures, and clonogenic cell survival, after doxorubicin treatment. Our results indicate that ATM contributes to the PRL-JAK2-STAT5-HSP90 pathway in mediating cellular resistance to DNA-damaging agents.
Insights
Prolactin (PRL) enhances breast cancer cell survival against DNA damage via the JAK2-STAT5-HSP90 pathway. ATM kinase is crucial, and inhibiting HSP90 or ATM synergizes with chemotherapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Prolactin (PRL) is a survival factor for breast cancer cells.
- The precise PRL signaling pathway and its mechanism remain largely unknown.
- Heat shock protein 90 (HSP90) alpha was previously identified as a target gene in the PRL-Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5) pathway.
Purpose of the Study:
- To investigate the role of HSP90 in PRL-mediated cell viability in response to DNA damage.
- To elucidate the involvement of the ataxia-telangiectasia mutated (ATM) kinase in this process.
- To explore potential therapeutic strategies by targeting this pathway.
Main Methods:
- Utilized breast cancer cell lines treated with DNA-damaging agents (doxorubicin, etoposide).
- Employed PRL receptor antagonist, HSP90 inhibitors (17-allylamino-17-demethoxygeldanamycin, BIIB021), JAK2 inhibitor (G6), and ATM inhibitor (KU55933).
- Assessed cell viability, protein levels (JAK2, ATM, p-ATM), and used short interfering RNA (siRNA) against ATM in various culture models.
Main Results:
- PRL significantly increased breast cancer cell viability following DNA damage, an effect blocked by a PRL receptor antagonist.
- HSP90 inhibitors reduced PRL-mediated viability and decreased levels of JAK2, ATM, and phosphorylated ATM.
- Inhibitors of JAK2 and ATM, as well as ATM siRNA, abolished PRL-induced cell survival, confirming pathway involvement and crosstalk.
- Drug synergism was observed between ATM/HSP90 inhibitors and doxorubicin.
Conclusions:
- ATM plays a critical role in the PRL-JAK2-STAT5-HSP90 pathway.
- This pathway mediates cellular resistance to DNA-damaging agents in breast cancer.
- Targeting HSP90 or ATM may enhance the efficacy of chemotherapy against breast cancer.
More Related Videos
08:41Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
Published on: December 27, 2024
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway